Pharmacy and Wellness Review
Volume 4

Issue 1

Article 4

January 2013

Comparing the GLP-1 Receptor Agonists: Byetta®, Victoza® and
once-weekly Bydureon™
Todd A. Tucker Jr.
Ohio Northern University

Sarah Turley
Ohio Northern University

Kaila Bollinger
Ohio Northern University

Jessica Beck
Ohio Northern University

Sandra L. Hrometz
Ohio Northern University

Follow this and additional works at: https://digitalcommons.onu.edu/paw_review
Part of the Endocrinology, Diabetes, and Metabolism Commons, Medical Pharmacology Commons,
and the Pharmaceutics and Drug Design Commons
This Article is brought to you for free and open access by
the ONU Journals and Publications at
DigitalCommons@ONU. It has been accepted for
inclusion in Pharmacy and Wellness Review by an
authorized editor of DigitalCommons@ONU. For more
information, please contact digitalcommons@onu.edu.

Endocrine

Comparing the GLP-1 Receptor Agonists:
Byetta®, Victoza® and once-weekly Bydureon™
Todd A. Tucker Jr .. fifth-year pharmacy student from Barnesville, Ohio; Sarah Turley, fourth-year pharmacy student from
Akron, Ohio; Kaila Bollinger, fourth-year pharmacy student from Bloomville, Ohio; Jessica Beck, fifth-year pharmacy
student from Gibsonburg, Ohio; Sandra L. Hrometz, BSPh '94, Ph.D., R.Ph., CGP, professor of pharmacology
Abstract
Type 2 diabetes mellitus (T2DM) has traditionally been managed with oral medications. However, in the last few years,
subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonists have risen to fame. These agents serve as a reliable addition to current monotherapy. GLP-1 receptor agonists offer
a significant reduction in hemoglobin AlC (HbAlc), fasting
plasma glucose, and have the added benefit of weight loss.
They work primarily by enhancing glucose-dependent insulin secretion while inhibiting glucagon secretion. The available GLP-1 agonists are Byetta® (exenatide), Victoza®
(liraglutide), and Bydureon™ (exenatide extended-release).
Studies suggest that they are similar in safety and efficacy,
with the longer acting GLP-1 receptor agonists, liraglutide
and extended-release exenatide, proving to be slightly more
efficacious in terms of HbAlc and weight reduction. All three
products have unique half-lives, dosing schedules, efficacies,
side effects and contraindications.
Introduction
GLP-1 Receptor Agonists and Their Role in Therapy
Glucagon-like peptide-1 (GLP-1) receptor agonists have
made a prominent appearance in the management of type 2
diabetes mellitus (T2DM) over recent years. Byetta®
(exenatide ), Victoza® (liraglutide), and once-weekly
Bydureon™ (extended-release exenatide) are the only GLP-1
agonists currently on the market. By acting as an agonist on
the GLP-1 receptor, they increase insulin secretion by pancreatic beta cells and inhibit glucagon secretion from pancreatic alpha cells.1 GLP-1 agonists have become a popular treatment option in T2DM for their glucose and body weight lowering properties.z Both the American Association of Clinical
Endocrinologists (AACE) and American Diabetes Association
(ADA) guidelines recommend GLP-1 agonists as add-on therapy for those who do not achieve adequate control on oral
monotherapy.3.4
GLP-1 is an incretin hormone secreted by the ileum, colon

and rectum. GLP-1 is produced within minutes of ingesting
food and is rapidly degraded by dipeptidyl peptidase-4 (DPP4). The GLP-1 receptor is a G-protein coupled receptor found
primarily on pancreatic alpha and beta cells. Activation of the
GLP-1 receptor in the pancreas results in increased insulin
secretion from beta cells and suppressed glucagon secretion
from alpha cells via a second messenger signal transduction
system involving cyclic adenosine monophosphate.s The existence of incretins was first realized when physicians noted
that ingested glucose correlated to a larger and more prolonged increase in insulin compared to intravenous glucose.
As seen in Table 1, GLP-1 receptor agonists also slow gastric
emptying, increase satiety and acutely increase disposal of
glucose in the periphery. Also, long-term use leads to pancreatic beta cell proliferation and an increase in overall insulin
synthesis. 2 In patients with T2DM, the incretin effect is impaired and incretin hormone activity is reduced, thus interfering with post-prandial insulin production.1 This is a very
important finding since the incretin effect contributes to
nearly two-thirds of insulin secretion in those with normal
glucose tolerance. Endogenous GLP-1 undoubtedly plays a
significant role in glucose homeostasis following oral glucose
consumption. Endogenous GLP-1 is rapidly metabolized by
DPP-4, resulting in a half-life of only one to two minutes.
Therefore, much attention has been given to understanding
the pharmacokinetic properties of GLP-1 receptor agonists
and making them more resistant to DPP-4 degradation as a
way of prolonging their half-lives. 1.6
Clinical trials have compared the addition of either a GLP-1
agonist or insulin to oral monotherapy in those patients with
inadequately controlled T2DM. 7,8,9 These studies show that
adding a GLP-1 receptor agonist to oral monotherapy lowers
HbAlc as much or even greater than the addition of insulin.7,8,9
In addition, GLP-1 agonists do not cause hypoglycemia and
actually promote weight loss;6 as such, they are used in par-

Table 1. Why Choose GLP-1 Receptor Agonists. 1' 2' 3' 4
Actions of GLP-1 Agonists
ACUTE
• Enhances glucose-dependent insulin secretion
• Inhibits glucagon secretion
• Slows rate of gastric emptying
• Increases satiety
• May increase glucose disposal in the periphery
CHRONIC
• Stimulates insulin synthesis
• Increases beta cell proliferation
• Promotes resistance to apoptosis
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Advantages

•
•
•

Weight Loss
Limited
hypoglycemia
Large decrease in
HbAlc
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Disadvantages

•

•
•
•
•

•

Gastrointestinal side effects
Route of administration (injection)
High Cost
Possible acute pancreatitis
C-cell hyperplasia/ medullary thyroid
tumors (liraglutide and extendedrelease exenatide)
Long-term safety unknown
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ticular in patients at high risk of hypoglycemia or when
weight loss is deemed appropriate.10 Although GLP-1 receptor agonists do not cause hypoglycemia, they may increase
the frequency of sulfonylurea-induced hypoglycemia when
given in combination. Physicians should therefore consider
reducing the sulfonylurea dose when initiating GLP-1
receptor agonist therapy.11 A review article by Marre and
Penfornis suggests that there may be a benefit to using GLP-1
agonists as an initial treatment for T2DM due to possible
protective effects on pancreatic beta cells in addition to positive effects on cardiovascular markers, including highdensity lipoprotein (HDL) levels, triglyceride levels, and diastolic blood pressure.1
Available Options
Byetta® (exenatide) was the first incretin mimetic to be introduced to the market in April 2005.12 Exenatide is a synthetic form of exendin-4, which is a natural GLP-1 present in
the saliva of the Gila monster.1 It is 53 percent homologous to
human GLP-1, but has a half-life of 2.4 hours as compared to
the one to two minute half-life of endogenous GLP-1. Byetta®
is administered subcutaneously (SQ) twice-daily, up to 60
minutes prior to breakfast and dinner (with at least six hours
between the two doses), due to its ability to reduce postprandial glucose (PPG) concentrations for approximately five
to eight hours. 13, 14 Exenatide appears to be well-tolerated.
The frequent adverse effect is nausea, which tends to subside
or become Jess severe as treatment progresses.11 To combat
the gastrointestinal side effects, doses are initiated at 5 mcg
twice-daily and titrated up to 10 mcg twice-daily in accordance with tolerability.1,ls Exenatide is renally eliminated,
therefore the product is not recommended in individuals
with a CrCl < 30 mL/min.13
Another side effect of exenatide is immunogenicity. Antiexenatide antibodies are reported to develop in 61 percent of
patients after a 26 week administration period. High levels of
anti-exenatide antibodies in patients were found to be associated with smaller mean HbAlc reductions.16
Victoza® (liraglutide) was approved by the Food and Drug
Administration (FDA) in January 2010. 12 Liraglutide is
97 percent homologous to native human GLP-1 with only an
amino acid substitution of arginine for lysine at position 35
and the addition of a fatty acid chain at position 26. These
minor modifications from endogenous GLP-1 increase halflife by promoting protein binding and facilitating selfassociation into heptamers, thus slowing absorption and
preventing DPP-4 degradation. 13.1 7 The extended half-life of
11 to 15 hours allows for once-daily dosing.17 Victoza® may
be administered without respect to food.1B
Liraglutide use is contraindicated in patients with a personal
or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2.
Unlike exenatide, decreased renal function has proven to
have little effect on the pharmacokinetics of liraglutide, but
because it is a relatively new drug caution should still be
used when treating renally impaired patients.rn
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A study of the immunogenicity of liraglutide has shown the
development of anti-liraglutide antibodies in 8.3 percent of
patients using liraglutide 1.8 mg after a 26 week period. The
presence of anti-liraglutide antibodies does not change the
glycemic response to liraglutide, as evidenced by similar
reductions in HbAlc in patients with and without the antibodies.16 Although these antibodies do not seem to alter the
efficacy, 40 percent of those patients developing antibodies
have developed infections, most commonly upper respiratory tract infections.is.19 The six Liraglutide Effect and Action
in Diabetes (LEAD-6) trials included investigations comparing the immunogenic responses of both exenatide and
liraglutide. They reported a greater immunogenic response
with exenatide compared to liraglutide and concluded that
this effect was due to the greater difference between amino
acid sequences between exenatide and endogenous human
GLP-1.

Once-weekly exenatide (Bydureon™) was approved in January 2012.12 Bydureon™ contains the same active ingredient
as the original exenatide twice-daily (Byetta®) formulation.
The extended-release characteristics come from the drug
being encapsulated in microspheres of medical grade poly(D,L-lactide-co-glycolide). The exenatide-containing microspheres slowly degrade in the body following SQ injection
and release the drug in a sustained-release manner. This provides for a low initial release rate while maintaining consistent therapeutic levels over a dosing interval. Bydureon™
comes as a dry powder and must be reconstituted by the patient. Both twice-daily exenatide and liraglutide come as solutions that are ready for injection. Unlike the twice-daily
product, once-weekly exenatide can be taken at any time of
day without regard to meals. 20 As with Victoza®, Bydureon™
is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.21
Literature Review
Recent trials have shown that both once-weekly exenatide
and once-daily liraglutide are superior to twice-daily exenatide when added to the treatment regimen of inadequately controlled type 2 diabetics.3,19,22 Two leading studies
comparing efficacy of the different GLP-1 agonists are detailed below. The first is the LEAD-6 trial, which compared
exenatide administered twice-daily (Byetta®) and liraglutide
(Victoza®).19 The second is the DURATION-1 trial, which
compared exenatide administered twice-daily (Byetta®) and
exenatide administered once-weekly (Bydureon™).22
Exenatide twice-daily versus liraglutide once-daily
(Byetta® versus Victoza®)19
Changes in HbAlc from baseline were measured in a 26
week randomized, open-label, active comparator, parallelgroup, multinational trial comparing liraglutide 1.8 mg SQ
once-daily to exenatide 10 µg SQ twice-daily.19 Inclusion
criteria included age between 18 and 80 years, diagnosis of
T2DM, HbAlc between 7 and 11 percent, body mass index
(BMI) of 45 kg/m 2 or Jess and no history of impaired liver or
renal function, clinically significant cardiovascular disease,
retinopathy or maculopathy requiring acute treatment, uncontrolled hypertension (as described by being~ 180/100
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mmHg), or cancer, as well as having been on stable treatment
with maximally tolerated doses of metformin, sulfonylurea,
or both for at least three months with no previous use of insulin, exenatide or liraglutide.
After randomization, participants underwent a two-week
liraglutide dose escalation period or a four-week exenatide
dose escalation period followed by a 22 to 24 week maintenance period. During the maintenance period, dose reduction
was not allowed and any participants who had intolerance to
the required study doses were removed from the study. Exenatide was administered zero to 60 minutes before breakfast and dinner (or before each of the two main daily meals
that are at least six hours or more apart), and liraglutide participants were encouraged to take liraglutide at the same
time each day.
The primary efficacy endpoint was the difference in HbAlc
from baseline to 26 weeks. Secondary efficacy endpoints included the proportion of patients reaching HbAlc targets,
changes in fasting plasma glucose, self-measured seven-point
plasma glucose profiles, [3-cell function, glucagon, blood pressure and lipid profiles. Safety variables included adverse
events, vital signs, electrocardiogram, biochemical and hematological measures and patient reported hypoglycemic episodes.
A total of 464 participants were randomly assigned to each
treatment group. Withdrawal rates were not significantly
different between the two treatment groups; the most common reason for withdrawal was adverse events. There were
no statistically significant differences in baseline therapy,
BMI, nationality or age. There was a statistically significant
difference of race between the two treatment groups; however, it is possible that this significance was due to the small
number of non-Caucasian participants in the study. The decrease in HbAlc values from baseline to week 26 was significantly greater in the liraglutide group. The proportion of participants achieving HbAlc targets was also significantly
higher in the liraglutide group. Both the amount and proportion of participants experiencing weight loss were similar
between the groups. Overall treatment satisfaction was reported to be significantly better in the liraglutide group;
however, liraglutide was found to have more serious adverse
events despite having an overall lower frequency of adverse
events. The incidence of nausea was initially found to be
similar between the groups, but was lower with liraglutide at
week 26.19
It is important to note that despite these positive results, the
open-label design may have affected the outcome by creating
bias in the study and possibly affecting patient expectations
and adherence to therapy. Additionally, the study was not
properly powered to assess differences between treatments
for rare clinical safety adverse events. Another issue is that
the majority of participants were Caucasian. This makes it
difficult to extrapolate the data to a more varied population,
even though there were no significant differences in baseline
characteristics of the participants. Even with the limitations
to the trial, it provides a direct comparison of efficacy and
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safety between liraglutide and exenatide over a 26-week period. Although additional studies are needed to investigate
long-term clinical benefits of liraglutide, the results show
that once-daily liraglutide provides a significantly greater
reduction in HbAlc and treatment satisfaction compared to
twice-daily exenatide. Liraglutide was also associated with
lower incidence of nausea (3 percent of treatment group)
compared to exenatide (9 percent of treatment group).
Exenatide once-weekly versus twice-daily (Bydureon™
versus Byetta®)22
Efficacy, safety and tolerability of once-weekly and twicedaily formulations of exenatide were compared in a 303 subject randomized, comparator-controlled, open-label trial.
Inclusion criteria were age of at least 16 years and diagnosis
of T2DM that had been treated for at least two months prior
to screening. Following the lead-in, the 295 patients remaining were divided into a 2 mg once-weekly exenatide group
and a twice-daily 10 µg exenatide group. During the trial,
patients self-administered exenatide after proper training.
Patients did not receive instruction on nutritional or caloric
restriction during the course of the study.22
The study tested the hypothesis that the change in HbAlc
from baseline achieved with once-weekly exenatide is noninferior to that of twice-daily exenatide at the end of 30
weeks of treatment. Secondary endpoints included safety
and tolerability, analysis of fasting and PPG concentrations,
body weight, fasting glucagon, fasting lipids, blood pressure,
and exenatide pharmacokinetics. The proportion of patients
achieving target HbAlc concentrations of 7.0 percent or less,
6.5 percent or less, and 6.0 percent or less was also recorded
during the study.
Withdrawal rates during the 30 week assessment, as well as
baseline demographics, were not found to be statistically
significant between the groups. Both treatment groups had
significant reductions in HbAlc by week six with the mean
reduction being significantly greater with exenatide onceweekly after ten weeks. This trend continued through the
remainder of the study. The mean difference of HbAlc levels
from baseline was 1.9 for once-weekly dosing and 1.5 in
twice-daily dosing. This reduction was found to be statistically significant for both groups. The HbAlc reductions were
consistent across all treatment background therapies for patients in both groups, and did not notably vary with sex or
age. It was also found that once-weekly dosing yielded a
greater proportion of patients achieving a HbAlc level of less
than 7.0 percent compared to the twice-daily dosing. Both
groups experienced significant reductions in body weight.
The most common adverse events in once-weekly dosing
were nausea and injection site pruritus, while the most common adverse effects in twice-daily dosing were nausea and
vomiting. The incidence of nausea was found to be significantly less in the once-weekly dosing. The authors concluded
that both treatment regimens significantly reduced baseline
HbAlc and body weight at the end of the 30 week treatment.
The significantly greater reduction in HbAlc observed for
once-weekly exenatide was thought to be due in part to the
continuous exposure of exenatide resulting in greater sup-
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pression of fasting glucagon and a corresponding reduction
in fasting glucose levels. It is also possible that the open-label
study biased the patients' expectations and adherence to
therapy, although this bias could have potentially affected
both forms of treatment. Despite this limitation, the reduction in HbAlc is consistent with a previous double-blind
placebo controlled study of extended-release exenatide
conducted by Kim et al. in 2007.24

misses a dose of Byetta® or Victoza®, they should skip that
dose and take the next dose at the normally scheduled time.
Doses should not be doubled. 14.lBlf a dose of Bydureon™ is
missed, it should be taken as soon as possible unless the next
regularly scheduled dose is less than three days away. In
other words, two doses of Bydureon™ should not be administered within a three day period.21

Cost-effectiveness
As these medications are relatively new to the market and
are available as brand-only products, many may question the
cost-effectiveness of such treatment. According to a 2011
article coming out of Europe, the improved life-expectancy,
reduced complication rates, and improved quality of life seen
with liraglutide make it a cost-effective choice in comparison
to twice-daily exenatide, despite the slightly higher lifetime
cost.25 There are no published studies on the costeffectiveness of once-weekly exenatide. Despite an increased
price, Bydureon™ offers even further improvements in clinical outcomes (weight loss and decreased HbAlc) and therefore may be a cost-effective alternative.

A once-monthly formulation of exenatide is currently being
developed. Phase 3 clinical trials are currently in consideration, although side effects and dosing concerns have been
raised. 1 2 There are several other GLP-1 agonists in the late
stages of development. These include lixisenatide, dulaglutide, albiglutide and taspoglutide. Albiglutide is unique in
that it is a recombinant GLP-1/albumin conjugate. It is conjugated with albumin to yield a longer half-life than Victoza®
and Byetta®.2

The Future and Investigational Drugs

Pharmacist Counseling
Patients using GLP-1 agonists for the treatment of T2DM
should be aware of their gastrointestinal side effects. Nausea,
the most common side effect, typically peaks within eight
weeks of treatment and usually resolves in 14 to 16 weeks.10
Vomiting, diarrhea or decreased appetite may also occur.
Those experiencing increased urination, severe abdominal
pain, difficulty swallowing, breathing problems, hypoglycemia, or persistent nausea, diarrhea or dizziness should contact their physician. Patients should be counseled on the dosing regimen of their particular therapy. Diet, exercise, glucose monitoring and regular lab testing should be a part of
the treatment regimen for all T2DM patients. If a patient

Conclusion
Since the introduction of Byetta® in 2005, GLP-1 receptor
agonists have become an increasingly popular therapy option in the maintenance of T2DM. The class has a great deal
to offer with proven efficacy in lowering fasting plasma glucose and HbAlc as well as minimal side effects and weight
loss. Although all three products are similar in their safety
and efficacy profiles, studies suggest that liraglutide and extended-release exenatide are more effective in lowering
HbAlc and body weight compared to twice-daily exenatide.
Extended release exenatide offers the additional benefit of
only being administered once-weekly perhaps improving
patient compliance and improved drug-related outcomes.
The GLP-1 receptor agonists have demonstrated significant
therapeutic benefits when added to the medication regimen
of type 2 diabetics inadequately controlled on initial monotherapy options .
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